Eli Lilly sues Par Pharmaceutical over testosterone treatment

Eli Lilly has sued Par Pharmaceutical for patent infringement over the drug Axiron (testosterone), used to treat men with low or no testosterone.

The complaint, filed on Friday, April 21 at the US District Court for the District of Delaware, alleges that Par infringed seven patents belonging to Eli Lilly when it submitted an Abbreviated New Drug Application with the Food and Drug Administration (FDA).

Par is seeking permission from the FDA to market a generic of Axiron.

The seven US patents involved are 8,435,944; 8,993,520; 9,180,194; 8,419,307; 8,177,449; 8,807,861; and 9,289,586.

Eli Lilly has asked the district court to enter a judgment which states that Par has infringed the seven patents.

The suing company has also asked the court to enjoin Par from bringing the generic to market, as well as an awa rd of costs for bringing the case.

Join us for a FREE webinar— Navigating the CRISPR IP landscape in Europe—on April 25th.

Did you enjoy reading this story?  Sign up to our free newsletter and get stories like this sent straight to your inbox.